Live Breaking News & Updates on Investor Relations Alnylam Pharmaceuticals Inc

Stay updated with breaking news from Investor relations alnylam pharmaceuticals inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Issues CRL for Patisiran in Treatment of ATTR Cardiomyopathy

Announced on October 9, the decision to issue a CRL is based on the FDA's belief the clinical meaningfulness of patisiran’s treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established. ....

United States , Kunzmannk Patisiran , Campbellp Patisiran , Ahmad Masri , Christopher Oconnor , Yvonne Greenstreet , Alnylam Pharmaceuticals , Investor Relations Alnylam Pharmaceuticals Inc , Oregon Health , Renal Drugs Advisory Committee , Vascular Institute , Hypertrophic Cardiomyopathy Center , Drug Administration , Sciences University , Complete Response Letter , Chief Executive Officer , Annual Congress , Heart Failure Association , European Society , New Drug Application , Christophero Connor , Inova Heart , Supplemental New Drug Application , Patisiran Onpattro , Attr Cm , Patisiran In Cardiomyopathy ,

Zilbesarian, an RNA Interference Agent, Shows Promise for Hypertension in Phase 1 Trial

A multipart, phase 1 trial provides evidence demonstrating the safety of zilbesarian, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension. ....

United Kingdom , United States , Simon Fox , Akshay Desai , Heart Failure Program , Alnylam Pharmaceuticals Inc , Investor Relations Alnylam Pharmaceuticals Inc , American Heart Association , Alnylam Pharmaceuticals , A Report From The American Heart Association , New England Journal , Advanced Heart Disease Section , Cardiovascular Division , England Journal , Investor Relations , Report From , Rna Intereference , Rna Agent , Alnylam And Roche ,

18-Month Data for Patisiran in ATTR with Amyloidosis Consistent with Primary Results

Data from the open-label extension period of the APOLLO-B trial provide new insight into the benefits of patisiran in patients with ATTR amyloidosis with cardiomyopathy. ....

Czech Republic , Renan Denoncourt , Marianna Fontana , International Symposium On Amyloidosis , Asian Society Of Cardiovascular Imaging Marianna Fontana , Alnylam Pharmaceuticals , Drug Administration , Investor Relations Alnylam Pharmaceuticals Inc , Asian Society , Cardiovascular Imaging , Annual Congress , Heart Failure Association , European Society , Heart Failure , New Drug Application , International Symposium , Honorary Consultant Cardiologist , National Amyloidosis Centre , University College London , Month Results , Investor Relations , Supplemental New Drug Application ,